Journal Policies Research Articles

Flashback Foreword: Cisplatin/Pemetrexed in Non–Small-Cell Lung Cancer

Article Tools FLASHBACK FOREWORD Article Tools OPTIONS & TOOLS Export Citation Track Citation Add To Favorites Rights & Permissions COMPANION ARTICLES Phase III Study Comparing Cisplatin Plus Gemcitabine With Cisplatin Plus Pemetrexed in Chemotherapy-Naive Patients With Advanced-Stage Non–Small-Cell Lung Cancer. May 05, 2023 ARTICLE CITATION DOI: 10.1200/JCO.22.02804 Journal of Clinical Oncology - published online before print May 5, 2023 PMID: 37146425 Flashback Foreword: Cisplatin/Pemetrexed in Non–Small-Cell Lung Cancer Thomas E. Stinchcombe , MD1,2xThomas E. StinchcombeSearch for articles by this author Show More 1Duke Cancer Institute, Division of Medical Oncology, Durham, NC2Associate Editor, Journal of Clinical Oncology, Alexandria, VA https://doi.org/10.1200/JCO.22.02804 First Page Full Text PDF Figures and Tables © 2023 by American Society of Clinical OncologyTHE TAKEAWAYThis phase III, noninferiority study1 investigated the novel chemotherapy combination of cisplatin and pemetrexed compared with the standard combination of cisplatin and gemcitabine demonstrating that survival was noninferior between the two platinum-based combinations, and a lower rate of grade 3 or 4 neutropenia and febrile neutropenia was observed with cisplatin and pemetrexed. However, cisplatin and pemetrexed demonstrated a superior survival in patients with adenocarcinoma and large cell histologies and inferior survival in patients with squamous histology, and after this trial, the use of pemetrexed was restricted to patients with nonsquamous histology.AUTHOR'S DISCLOSURES OF POTENTIAL CONFLICTS OF INTERESTFlashback Foreword: Cisplatin/Pemetrexed in Non–Small-Cell Lung CancerThe following represents disclosure information provided by the author of this manuscript. All relationships are considered compensated unless otherwise noted. Relationships are self-held unless noted. I = Immediate Family Member, Inst = My Institution. Relationships may not relate to the subject matter of this manuscript. For more information about ASCO's conflict of interest policy, please refer to www.asco.org/rwc or ascopubs.org/jco/authors/author-center.Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments).Thomas E. StinchcombeThis author is an Associate Editor for Journal of Clinical Oncology. Journal policy recused the author from having any role in the peer review of this manuscript.Consulting or Advisory Role: EMD Serono, Janssen Oncology, Turning Point Therapeutics, Sanofi/Aventis, GlaxoSmithKline, Genentech/Roche, Daiichi Sankyo/Astra Zeneca, Takeda, Eisai/H3 Biomedicine, G1 Therapeutics, Spectrum PharmaceuticalsResearch Funding: AstraZeneca (Inst), Takeda (Inst), Regeneron (Inst), Seattle Genetics (Inst), Mirati Therapeutics (Inst), Genentech/Roche (Inst)No other potential conflicts of interest were reported. Companion Phase III Study Comparing Cisplatin Plus Gemcitabine With Cisplatin Plus Pemetrexed in Chemotherapy-Naive Patients With Advanced-Stage Non–Small-Cell Lung Cancer

Balkan Medical Journal Policy on the Use of Chatbots in Scientific Publications

Balkan Medical Journal Policy on the Use of Chatbots in Scientific Publications

Reports of practitioners’ use of public affairs faculty published research

ABSTRACT Using a unique dataset built around published papers in top quality public policy, public administration and program evaluation journals, we find that 29.7% of respondent authors indicate that the knowledge from their articles was used by policymakers or public administrators. These data are used to test for different patterns of use for policy vs management knowledge. Findings suggest that journal quality positively affects policy use but negatively affects management use and that topics suggested by practitioners affect management use but not policy use. The researchers’ degree of motivation to have their work used is important in both types of knowledge use. Overall, the results suggest there may be greater spillovers to practical use derived from standard academic publishing pursuits than generally believed.

Flashback Foreword: Bevacizumab + Carboplatin/Paclitaxel in NSCLC

Article Tools FLASHBACK FOREWORD Article Tools OPTIONS & TOOLS Export Citation Track Citation Add To Favorites Rights & Permissions COMPANION ARTICLES Randomized Phase II Trial Comparing Bevacizumab Plus Carboplatin and Paclitaxel With Carboplatin and Paclitaxel Alone in Previously Untreated Locally Advanced or Metastatic Non-Small-Cell Lung Cancer. April 26, 2023 ARTICLE CITATION DOI: 10.1200/JCO.22.02790 Journal of Clinical Oncology - published online before print April 26, 2023 Flashback Foreword: Bevacizumab + Carboplatin/Paclitaxel in NSCLC Thomas E. Stinchcombe , MD1,2xThomas E. StinchcombeSearch for articles by this author Show More 1Associate Editor, Journal of Clinical Oncology, Alexandria, VA2Duke Cancer Institute, Durham, NC https://doi.org/10.1200/JCO.22.02790 First Page Full Text PDF Figures and Tables © 2023 by American Society of Clinical OncologyTHE TAKEAWAYThis randomized phase II trial1 compared carboplatin and paclitaxel alone (the control arm) with carboplatin and paclitaxel with bevacizumab at two doses in patients with non–small-cell lung cancer (NSCLC). Bevacizumab 15 mg/kg once every 3 weeks was the dose selected for future clinical trials, and an excessive rate of toxicity was observed in the subset of patients with squamous histology, leading to the exclusion of patients with NSCLC with squamous histology from future trials of bevacizumab in NSCLC.AUTHOR'S DISCLOSURES OF POTENTIAL CONFLICTS OF INTERESTFlashback Foreword: Randomized Phase II Trial Comparing Bevacizumab Plus Carboplatin and Paclitaxel With Carboplatin and Paclitaxel Alone in Previously Untreated Locally Advanced or Metastatic Non–Small-Cell Lung CancerThe following represents disclosure information provided by the author of this manuscript. All relationships are considered compensated unless otherwise noted. Relationships are self-held unless noted. I = Immediate Family Member, Inst = My Institution. Relationships may not relate to the subject matter of this manuscript. For more information about ASCO's conflict of interest policy, please refer to www.asco.org/rwc or ascopubs.org/jco/authors/author-center.Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments).Thomas E. StinchcombeThis author is an Associate Editor for Journal of Clinical Oncology. Journal policy recused the author from having any role in the peer review of this manuscript.Consulting or Advisory Role: EMD Serono, Janssen Oncology, Turning Point Therapeutics, Sanofi/Aventis, GlaxoSmithKline, Genentech/Roche, Daiichi Sankyo/Astra Zeneca, Takeda, Eisai/H3 Biomedicine, G1 Therapeutics, Spectrum PharmaceuticalsResearch Funding: AstraZeneca (Inst), Takeda (Inst), Regeneron (Inst), Seattle Genetics (Inst), Mirati Therapeutics (Inst), Genentech/Roche (Inst)No other potential conflicts of interest were reported. Companion Randomized Phase II Trial Comparing Bevacizumab Plus Carboplatin and Paclitaxel With Carboplatin and Paclitaxel Alone in Previously Untreated Locally Advanced or Metastatic Non-Small-Cell Lung Cancer

Authors' conflicts of interest in Nepalese healthcare journals.

Most biomedical journals now require authors to declare their conflicts of interest (COI), especially financial ones, before they accept the manuscript for submission. This study aims to examine the COI policies of Nepalese healthcare journals. The sample constituted journals indexed in Nepal Journals Online (NepJOL) as of June 2021. Of the 68 that met our inclusion criteria, 38(55.9%) journals endorsed the COI policy of the International Committee of Medical Journal Editors. Thirty-six (52.9%) journals had a policy for reporting the COI. Financial COI was the only type of COI mentioned. All journals in Nepal are encouraged to request the authors to declare the COI for better transparency.

Training and capacity building of young water professionals—role of an innovative and transformative program for sustainable water futures

AbstractWater management has become quite a complex task because of population pressure, climate change, and urbanization. Future young water professionals (YWPs) need to be capable of working with real‐world situations, and they need to be trained suitably so that they can effectively communicate with decision‐makers and enable innovative ideas to be adopted in policy development and actions on the ground. To get the ideas converted into actions, we need YWPs who are well‐trained not only in water science and engineering but also in social, economic, governance, policy, and other related aspects. Overall, well‐designed transdisciplinary training can help YWPs to bring new thinking and leadership in their workplace, including water governance, stakeholder involvement, critical thinking, problem analysis, and effective communication in various situations. Furthermore, such training can help YWPs develop their vision and capacity for more effective planning, design, implementation, and management of water projects and initiatives. As part of their training, YWPs need to develop their competencies, namely, problem‐solving, transdisciplinary and systemic thinking, and effective communication, through working on real‐world projects of selected clients. The next issue of World Water Policy Journal will be a Special Issue focusing on the work of YWPs involved in two initiatives in South Asia. Activities through the Australia–India Water Centre Program for capacity building for Indian YWPs in Sustainable Water Futures will be one of the initiatives presented.

Policies Affecting Pregnant Women with Substance Use Disorder

Policies Affecting Pregnant Women with Substance Use Disorder

Flashback Foreword: Pemetrexed and Cisplatin in Mesothelioma

Article Tools FLASHBACK FOREWORD Article Tools OPTIONS & TOOLS Export Citation Track Citation Add To Favorites Rights & Permissions COMPANION ARTICLES Phase III Study of Pemetrexed in Combination With Cisplatin Versus Cisplatin Alone in Patients With Malignant Pleural Mesothelioma. April 17, 2023 ARTICLE CITATION DOI: 10.1200/JCO.22.02720 Journal of Clinical Oncology - published online before print April 17, 2023 PMID: 37068376 Flashback Foreword: Pemetrexed and Cisplatin in Mesothelioma Thomas E. Stinchcombe , MD1,2xThomas E. StinchcombeSearch for articles by this author Show More 1Division of Medical Oncology, Duke Cancer Institute, Durham, NC2Associate Editor, Journal of Clinical Oncology, Alexandria, VA https://doi.org/10.1200/JCO.22.02720 First Page Full Text PDF Figures and Tables © 2023 by American Society of Clinical OncologyTHE TAKEAWAYIn 2003, Vogelzang et al1 published a phase III trial, which demonstrated a superior overall survival, time to progression, and response rate with cisplatin and pemetrexed compared with cisplatin in patients with malignant pleural mesothelioma. At the time this trial was performed, there were doubts about the efficacy of chemotherapy in this disease, and this trial validated chemotherapy as an effective treatment, and platinum-pemetrexed became the standard first-line treatment for the next 2 decades.AUTHOR'S DISCLOSURES OF POTENTIAL CONFLICTS OF INTERESTFlashback Foreword: Pemetrexed and Cisplatin in MesotheliomaThe following represents disclosure information provided by the author of this manuscript. All relationships are considered compensated unless otherwise noted. Relationships are self-held unless noted. I = Immediate Family Member, Inst = My Institution. Relationships may not relate to the subject matter of this manuscript. For more information about ASCO's conflict of interest policy, please refer to www.asco.org/rwc or ascopubs.org/jco/authors/author-center.Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments).Thomas E. StinchcombeThis author is an Associate Editor for Journal of Clinical Oncology. Journal policy recused the author from having any role in the peer review of this manuscript.Consulting or Advisory Role: EMD Serono, Janssen Oncology, Turning Point Therapeutics, Sanofi/Aventis, GlaxoSmithKline, Genentech/Roche, Daiichi Sankyo/Astra Zeneca, Takeda, Eisai/H3 Biomedicine, G1 Therapeutics, Spectrum PharmaceuticalsResearch Funding: AstraZeneca (Inst), Takeda (Inst), Regeneron (Inst), Seattle Genetics (Inst), Mirati Therapeutics (Inst), Genentech/Roche (Inst)No other potential conflicts of interest were reported. Companion Phase III Study of Pemetrexed in Combination With Cisplatin Versus Cisplatin Alone in Patients With Malignant Pleural Mesothelioma

Data and reproducibility. Interpretation of international guidelines and journals’ best policies and practices

Relevance. The 2022 Update of the COPE, DOAJ, OASPA, and WAME joint guidelines on The Principles of Transparency and Best Practice in Scholarly Publishing encourages journals to establish their own policy in “data sharing and reproducibility” (DS&R). However, this document neither provides detailed recommendations / templates nor explains the reproducibility crisis phenomenon.Objectives. To analyze and interpret the international guidelines, the best practices of global publishers and journals, as well as typical mistakes and experience of selected Russian journals, to help a journal develop its own DS&R policy and its implementation.Materials and methods. The analysis of various sources (literature, reporting guidelines, data repositories), policies of 83 Russian university journals, as well as policies of the top 5 international publishers and their journals. Interviews with 6 editors-in-chief of Russian journals regarding DS&R.Results. All the top 5 global publishers in their DS&R policy adapt the TOP Guidelines and offer their own data sharing statement templates. Discussion and interpretations. The author suggests Russian translation of the TOP Guidelines and the main templates (e.g., data sharing statement). He also discusses 9 best journal policies and practices (including pre-registration studies).Conclusions. Numerous international sources, as well as the experience of selected Russian journals, demonstrate that the implementation of the DS&R policy increases articles citation (averagely by 25.3%), the growth of journal’s bibliometric and altmetric indicators, and also contributes to the trust of the target audience. As a result, it strengthes the journal portfolio to enable publishing articles well ahead of schedule. However, only the declarative statement of DS&R policies by journals without proper implementation does not bring tangible benefits to the journals.

Flashback Foreword: Pazopanib in Renal Cell Carcinoma and Overall Survival With Sunitinib Versus Interferon-α in Metastatic Renal Cell Carcinoma

Article Tools FLASHBACK FOREWORD Article Tools OPTIONS & TOOLS Export Citation Track Citation Add To Favorites Rights & Permissions COMPANION ARTICLES Pazopanib in Locally Advanced or Metastatic Renal Cell Carcinoma: Results of a Randomized Phase III Trial. April 05, 2023 Overall Survival and Updated Results for Sunitinib Compared With Interferon Alfa in Patients With Metastatic Renal Cell Carcinoma. April 05, 2023 ARTICLE CITATION DOI: 10.1200/JCO.23.00153 Journal of Clinical Oncology - published online before print April 5, 2023 PMID: 37018918 Flashback Foreword: Pazopanib in Renal Cell Carcinoma and Overall Survival With Sunitinib Versus Interferon-α in Metastatic Renal Cell Carcinoma Michael A. Carducci, MD1,2xMichael A. CarducciSearch for articles by this author Show More 1Associate Editor, Journal of Clinical Oncology, Alexandria, VA2Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins, Baltimore, MD https://doi.org/10.1200/JCO.23.00153 First Page Full Text PDF Figures and Tables © 2023 by American Society of Clinical OncologyTHE TAKEAWAYIn 2009, Motzer et al1 demonstrated an overall survival advantage for sunitinib over interferon-α in metastatic clear cell renal carcinoma; in 2010, Sternberg et al2 demonstrated an 8-month improvement in progression-free survival over placebo in the same patient population as sunitinib. These two reports laid the foundation for vascular endothelial growth factor tyrosine kinase inhibition therapy in renal cancer and forming the building blocks for immune checkpoint combination therapies now used in clinical practice further extending the lives of patients with advanced renal cell carcinoma.AUTHOR'S DISCLOSURES OF POTENTIAL CONFLICTS OF INTERESTFlashback Foreword: Pazopanib in Renal Cell Carcinoma and Overall Survival With Sunitinib Versus Interferon-α in Metastatic Renal Cell CarcinomaThe following represents disclosure information provided by the author of this manuscript. All relationships are considered compensated unless otherwise noted. Relationships are self-held unless noted. I = Immediate Family Member, Inst = My Institution. Relationships may not relate to the subject matter of this manuscript. For more information about ASCO's conflict of interest policy, please refer to www.asco.org/rwc or ascopubs.org/jco/authors/author-center.Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments).Michael A. CarducciThis author is an Associate Editor for Journal of Clinical Oncology. Journal policy recused the author from having any role in the peer review of this manuscript.Consulting or Advisory Role: Pfizer, Acrivon Therapeutics, AstraZeneca, SanofiResearch Funding: Pfizer (Inst), Arcus Biosciences (Inst), Merck (Inst), Celgene/Bristol Myers Squibb (Inst)No other potential conflicts of interest were reported. Companion Pazopanib in Locally Advanced or Metastatic Renal Cell Carcinoma: Results of a Randomized Phase III Trial Overall Survival and Updated Results for Sunitinib Compared With Interferon Alfa in Patients With Metastatic Renal Cell Carcinoma

Cryptococcal meningitis with suspected concomitant neurosyphilis in an immunocompetent individual: A diagnostic dilemma

No abstract available.

The trouble with normalisation: Transformations to hepatitis C health care and stigma in an era of viral elimination.

Modern health-care systems have customarily approached hepatitis C in ways that resemble the public health approach to HIV/AIDS known as 'HIV exceptionalism'. HIV exceptionalism describes the unusual emphasis on privacy, confidentiality and consent in approaches to HIV and was partly developed to address HIV/AIDS-related stigma. In the case of hepatitis C, exceptionalist approaches have included diagnosis and treatment by specialist physicians and other 'boutique' public health strategies. The recent availability of highly effective, direct-acting antivirals alongside goals to eliminate hepatitis C have heralded dramatic changes to hepatitis C health care, including calls for its 'normalisation'. The corollary to exceptionalism, normalisation aims to bring hepatitis C into routine, mainstream health care. This article draws on interviews with stakeholders (n=30) who work with hepatitis C-affected communities in policy, community, legal and advocacy settings in Australia, alongside Fraser etal.'s (2017, International Journal of Drug Policy, 44, 192-201) theorisation of stigma, and Rosenbrock etal.'s (1999, The AIDS policy cycle in Western Europe: from exceptionalism to normalisation. WZB Discussion Paper, No. P 99-202) critique of normalisation to consider the perceived effects of hepatitis C normalisation. Stakeholders described normalisation as a stigma-reducing process. However, they also expressed concerns about the ongoing stigma and discrimination that is not ameliorated by normalisation. We suggest that in centring normalisation, changes in health care may exaggerate the power of technological solutions to transform the meanings of hepatitis C.

Exploring Nigeria’s Public Projects Prospects for the Good of Nigerians

Public projects that should facilitate wellbeing of Nigerians have suffered setbacks and not been able to do so. This study is a descriptive type and discussed the forces of projects failure, intrigues of public officers that subvert project outcomes, the expected roles of state actors in project pursuits, and prospects for public projects in Nigeria. The study found that paucity of funds, policy summersault, and inflation of projects costs, poor delivery of projects or outright abandonment by contractors, attitudes of the ruling regime, its successor and beneficiaries are some of the forces that obstruct public projects. The study also found that corruption, use of direct labor, connivance; party politics, poor focus and maintenance, personalization of public project, misplaced priority are some of the intrigues of project initiators that subvert project outcomes in Nigeria. The study also found that numerous skilled bureaucrats, due process, procurement system, and supremacy of the constitution, multi-party politics, and the presidential system of government with democratic system that Nigeria practices are some of the opportunities open to the country on its public projects fortune. This study made use of secondary data that was sourced from journal articles, online materials, government gazettes, policy documents, and other publications. The data was content analyzed thematically. The study concluded that members of the public need to make attainable gains from numerous public project opportunities. Keywords: project initiator, opportunities, public projects, masses, wellbeing of Nigerians DOI: 10.7176/PPAR/13-3-01 Publication date: April 30 th 2023

Survey and analysis of the data policy of the journals listed in the Excellence Action Plan for China's STM Journals Program for example

As an important output of scientific research, scientific data play an important role in scholarly communication. The establishment of the data policy of STM journals is of great significance to promote the data sharing, data reuse, data citation and scientific research evaluation. In this paper, by means of literature research and online research and based on the information published on journal websites, we surveyed the data policies operation status of 302 STM journals that were selected as the leading journals, key journals, and echelon journals in the Excellence Action Plan for China's STM Journals. Then we statistically analyzed the data policy setting, and the features of the policy, such as classification types, data availability, and data citation. The survey shows the current practice progress of China’s high-level STM journals related to scientific data publishing. Among the statistical journal sources, 81.82% of leading journals, 62.07% of key journals, 34.67% of echelon journals and 69.23% of high-starting new journals have formulated relevant data policies. According to survey results, the publication of data in STM journals has been widely recognized as one of the effective ways to promote scientific data sharing. Presently, all major publishing institutions have developed relevant data policies. Compared with the international counterparts, the data publishing of China’s STM journals still has a long way to go in industry recognition and framework strategy, and it is urgent to develop a universal data policy framework for different journals and publishers.

Hysteroscopic resection of cervical ectopic pregnancy: A case report

No abstract available

Factors of Indonesia Economic Growth (2017-2022)

Economic growth is measured by changes in a country’s Gross Domestic Product (GDP), which can be unraveled into the population and economic elements. This research is conducted to find trends and identify publications on economic growth in Indonesia in the 2017–2022 period. The data collection techniques by downloading files from the Scopus database to see publication trends with the highest number of documents, ranking classifications of institutions or universities, journals, and documents, and using shared keywords. The method used is bibliometric analysis. A total of 168 documents collected from the Publish or Perish (PoP) application using the Scopus database were combined into one file in RIS format and entered into the VOSviewer application to obtain network visualization and overlay visualization. The study results show that the trend of publications related to economic growth in Indonesia for the last six years has decreased yearly. The highest number of documents is in the “International Journal of Energy Economics and Policy,” with 20 documents, followed by the Haseeb (2019) article, totaling 120 citations. Based on the keywords that have been visualized, several keywords are factors of economic growth in Indonesia from 2017 to 2022, namely Energy Consumption, Investment, CO2 Emissions, Education, GDP, Inflation, FDI, Exchange Rate, Export, Government Expenditure, Income Inequality, Inequality, Human Capital, Human Development Index, and Sustainable Development.

Molecular Microbiology, one health, one planet

Molecular Microbiology is seeking original research and review articles for a special section that will focus on the One Health initiative and the Sustainable Development Goals of the United Nations. These initiatives are geared toward increasing scientific knowledge and developing molecular tools to monitor and control microbial activities with an emphasis on helping the global community tackle infectious diseases, promote sustainable agriculture, and protect the environment. To support research communities working at the intersection of microbiology, health, climate, and sustainable research, Molecular Microbiology is introducing a new section called “One Health Microbiology.” This section will cover a broad range of disciplines, including infectious diseases, molecular biology, environmental sciences, biotechnology, immunology, pharmaceutical sciences, food sciences, social sciences, economics, and multidisciplinary sciences. The aim is to provide a holistic view of the field and offer high-quality, interdisciplinary content that meets the highest standards. The journal is now calling for contributions to create an authoritative collection of articles that will present research, concepts, and challenges related to One Health initiatives. The articles should be of interest to a wide audience, address challenging scientific questions, offer biological or mechanistic insights, propose solutions to existing problems, or provide a perspective on the future of the field. While the journal encourages submissions of original research or review articles, all types of articles will be considered. The initial deadline for submission is July 15, 2023, with a secondary target submission date of September 30, 2023. To submit a manuscript to Molecular Microbiology's “One Health Microbiology” section, authors must follow the Author Guidelines and use the journal's online submission system. During the submission process, authors are asked to clearly indicate that their contribution is intended for this section. All submitted manuscripts will be peer-reviewed according to the journal's publishing policies. Accepted articles will be published online without charge. While authors are not required to pay Article Processing Charges (APCs), they have the option to publish their article as open access. If they choose this option, Wiley may cover the APCs through agreements with institutions and funders globally. Section Editors: Neil Gow, University of Exeter, Exeter, United Kingdom Leah Cowen, University of Toronto, Canada Monica Gandhi, University California San Francisco, United States Nicole De Nisco, University Texas Dallas, United States Jacomine Krijnse Locker, Paul Ehrlich Institut, Germany Friedrich Frischknecht, Heidelberg University, Germany Junior Editors: Daniel Fernando Rojas Tapias, Agrosavia, Mosquera, Colombia Michael Neugent, University Texas Dallas, United States

Metrics for maternity unit staffing in low resource settings: Scoping review and proposed core indicator.

The lack of usable indicators and benchmarks for staffing of maternity units in health facilities has constrained planning and effective program implementation for emergency obstetric and newborn care (EmONC) globally. To identify potential indicator(s) and benchmarks for EmONC facility staffing that might be applicable in low resource settings, we undertook a scoping review before proceeding to develop a proposed set of indicators. Population: women attending health facilities for care around the time of delivery and their newborns. Concept: reports of mandated norms or actual staffing levels in health facilities. studies conducted in healthcare facilities of any type that undertake delivery and newborn care and those from any geographic setting in both public and private sector facilities. Searches were limited to material published since 2000 in English or French, using Pubmed and a purposive search of national Ministry of Health, non-governmental organization and UN agency websites for relevant documents. A template for data extraction was designed. Data extraction was undertaken from 59 papers and reports including 29 descriptive journal articles, 17 national Ministry of Health documents, 5 Health Care Professional Association (HCPA) documents, two each of journal policy recommendation and comparative studies, one UN Agency document and 3 systematic reviews. Calculation or modelling of staffing ratios was based on delivery, admission or inpatient numbers in 34 reports, with 15 using facility designation as the basis for staffing norms. Other ratios were based on bed numbers or population metrics. Taken together, the findings point to a need for staffing norms for delivery and newborn care that reflect numbers and competencies of staff physically present on each shift. A Core indicator is proposed, "Monthly mean delivery unit staffing ratio" calculated as number of annual births/365/monthly average shift staff census.

Editorial: Three intellectual debts and the three horses of entrepreneurship. The Journal of Entrepreneurship and Public Policy celebrates ten years

Editorial: Three intellectual debts and the three horses of entrepreneurship. The Journal of Entrepreneurship and Public Policy celebrates ten years

RETRACTED ARTICLE: Pushing low-carbon mobility: a survey experiment on the public acceptance of disruptive policy packages

We, the Editor[s] and Publisher of Climate Policy, have retracted the following article: We, the authors, Editors and Publisher of the journal Climate Policy, have retracted the following article: Thaller, A., Wicki, M., Fleiß, E., Maier, R., Posch, A. (2023). Pushing low-carbon mobility:A survey experiment on the public acceptance of disruptive policy packages, Climate Policy,' 1–13, doi:10.1080/14693062.2023.2182755 After its publication, we have identified a coding error within the data cleaning file, leading to the incorrect labelling of some attributes for the main analysis of the choice experiment. As this alters the results and conclusions for some of the policies examined (particulady the ICEV registration and use bans, car-free centres, and street redesign policies), the authors alerted the issue to the Editors and Publisher, and all have agreed to retract the article to ensure the integrity of the scholarly record. The authors have been invited to resubmit the correctäd version of the article for review and consideration for publication. We have been informed in our decision-making by our editorial policies and the COPE guidelines. We deeply regret this error and sincerely apologize for any confusion it may have caused. We are committed to the highest standards of research and appreciate the understanding of our readers and peers in this matter. The retracted article will remain online to maintain the scholarly record, but it will be digitally watermarked on each page as “Retracted”.